Morgan Stanley trimmed its position in shares of Express Scripts Holding Co (NASDAQ:ESRX) by 36.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 967,028 shares of the company’s stock after selling 546,195 shares during the period. Morgan Stanley’s holdings in Express Scripts were worth $74,662,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Express Scripts by 1.5% during the 2nd quarter. BlackRock Inc. now owns 35,424,185 shares of the company’s stock valued at $2,735,103,000 after acquiring an additional 538,578 shares in the last quarter. Marco Investment Management LLC boosted its position in shares of Express Scripts by 168.2% in the 2nd quarter. Marco Investment Management LLC now owns 79,246 shares of the company’s stock worth $6,119,000 after purchasing an additional 49,696 shares in the last quarter. Commonwealth Bank of Australia boosted its position in shares of Express Scripts by 15.6% in the 2nd quarter. Commonwealth Bank of Australia now owns 296,858 shares of the company’s stock worth $22,915,000 after purchasing an additional 39,983 shares in the last quarter. Hendershot Investments Inc. boosted its position in shares of Express Scripts by 2.7% in the 2nd quarter. Hendershot Investments Inc. now owns 89,125 shares of the company’s stock worth $6,881,000 after purchasing an additional 2,380 shares in the last quarter. Finally, ING Groep NV boosted its position in shares of Express Scripts by 1.9% in the 2nd quarter. ING Groep NV now owns 138,146 shares of the company’s stock worth $10,666,000 after purchasing an additional 2,640 shares in the last quarter. 84.69% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently commented on the company. BidaskClub cut Express Scripts from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Zacks Investment Research cut Express Scripts from a “hold” rating to a “sell” rating in a research report on Monday, July 23rd. ValuEngine raised Express Scripts from a “hold” rating to a “buy” rating in a research report on Monday, September 17th. Credit Suisse Group cut Express Scripts from an “outperform” rating to a “neutral” rating and boosted their price target for the stock from $90.00 to $96.50 in a research report on Tuesday, September 18th. Finally, William Blair raised Express Scripts from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 1st. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $86.36.
Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Wednesday, August 1st. The company reported $2.22 earnings per share for the quarter, topping analysts’ consensus estimates of $2.20 by $0.02. Express Scripts had a net margin of 4.65% and a return on equity of 25.49%. The company had revenue of $25.64 billion during the quarter, compared to analyst estimates of $25.43 billion. During the same period in the previous year, the business earned $1.73 EPS. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. sell-side analysts expect that Express Scripts Holding Co will post 9.07 earnings per share for the current fiscal year.
In related news, insider Christine Houston sold 12,898 shares of the business’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $85.00, for a total value of $1,096,330.00. Following the completion of the transaction, the insider now directly owns 110,908 shares in the company, valued at approximately $9,427,180. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.79% of the stock is owned by insiders.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Recommended Story: How to Track your Portfolio in Google Finance
Want to see what other hedge funds are holding ESRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Express Scripts Holding Co (NASDAQ:ESRX).
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.